← Back to news

Markets

JPMorgan builds $2.93 billion stake in health care stock

Y

Has Chinese light vehicle demand peaked?

Y

Goldman Sachs sends harsh warning to U.S. credit card users

Y

Michael Burry made $100M by betting against the housing market in 2008, now he’s set his sights on AI with these moves

Y

BILL Stock Down 24%, Core Revenue Up 17%: Why a 14% Portfolio Bet Signals Conviction

Y

Chemed Stock Down 15% in a Year as One Fund Builds a $5.56 Million Stake

Y

3 Dirt Cheap Stocks to Buy With $1,000 Right Now

Y

Billionaire BlackRock CEO Larry Fink Says 'Almost No One Is Close' To Saving The Nearly $2.1M Americans Claim They Need For A Comfortable Retirement

Y

Trump Declares 'Largest Tax Refund Season Ever' In 2026: 'One Big Beautiful Bill' Secures Everything Needed Until 2030

Y

Vitalik Buterin: Hedging on Prediction Markets Could 'Replace Fiat Currency'

Y

Up 50% in One Year: Why a Fund Cut $5 Million in TriMas Stock but Held Onto a 3% Position

Y

Metaplanet Posts $605 Million Loss After Spending Billions on Bitcoin

Y

Intel Stock Has Gotten Way Ahead of Lip-Bu Tan's Turnaround Plans. Will Investors Regret Buying?

Y

Real Estate Rebound? The 3X Play for Investors Betting on a Commercial Property Pivot

Y

What Makes BioMarin (BMRN) so Attractive

Y

Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough

Y

FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN)

Y

Soleno Therapeutics (SLNO) Sparks Confidence Amid Topline Outperformance

Y

FDA-Issued CRL for Relacorilant NDA Leads to Bullish Views Around Corcept Therapeutics (CORT)

Y

Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE)

Y

Wave Life Sciences (WVE) to Benefit From Optimism Surrounding Alpha-1 Antitrypsin Deficiency Program

Y

Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry

Y

Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX)

Y

Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating

Y

Here is Why Beam Therapeutics (BEAM) Appears so Attractive

Y

Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX)

Y

Orexin-2 Receptor Data Reinforces a Positive Outlook for Centessa (CNTA)

Y

Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026

Y

Atacicept’s Potential Approval Drives Favorable Views on Vera Therapeutics (VERA)

Y

Arcellx (ACLX) Shares Encouraging Data on Latest Laboratory Study

Y

Here is Why Apogee Therapeutics (APGE) Appears Attractive

Y

Timely Tips And Tools On How To Invest In Stocks In This Market

Y

Prediction: 2 Stocks That Will Be Worth More Than Amazon 3 Years From Now

Y

Apollo Global Management Touts $40T Private Credit Opportunity, AI Financing and Fund XI at BofA Conference

Y

They're Complete Opposites. He Saved More Than $100K And Pays For Everything, While She's $80K In Debt. 'I Ain't Saying She's The Gold Digger'

Y

Great Wall Motor plans Europe relaunch with hybrids and local plant

Y

Gold, XRP extend losses on Presidents’ Day

Y

This AI Stock Just Became Wall Street's Most Controversial Pick for 2026

Y

Bitcoin 'Boom-Bust' Era Is Over as Institutions Take the Lead: WisdomTree

Y

3 Stock Updates You'll Want to Watch This Week

Y

UBS Still Neutral on East West Bank (EWBC)

Y

UBS Retained Buy Recommendation on SouthState Bank (SSB)

Y

Commerce Bank (CBSH) Declares Dividends of $0.2750 per Share

Y

UBS Keeps Buy Rating on Western Alliance (WAL)

Y

JP Morgan Increases Target Price on Huntington Bancshares (HBAN) to $21

Y

Evercore ISI Raises Price Target on Pinnacle Financial (PNFP) to $116, Keeps Overweight Call

Y

JP Morgan Raises Target Price on Truist Financial (TFC) to $47, Keeps Neutral Call

Y

JP Morgan Overweight on BNY Mellon (BK) with a Target Price of $128.50

Y

Baird Upgrades Wells Fargo (WFC) to Neutral

Y

JP Morgan Raises Target Price on Citi (C), Keeps Overweight Call

Y